My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 217

    1.

    Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.

    Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y.

    Diabetes. 2001 May;50(5):1166-70.PMID: 11334422 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Response of experimental retinal neovascularization to thiazolidinediones.

    Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, Hinton DR.

    Arch Ophthalmol. 2001 May;119(5):709-17.PMID: 11346398 [PubMed - indexed for MEDLINE]Related articles

    3.

    Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.

    Tafuri SR.

    Endocrinology. 1996 Nov;137(11):4706-12.PMID: 8895337 [PubMed - indexed for MEDLINE]Related articles

    4.

    Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells.

    Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y.

    Biochem Biophys Res Commun. 2000 May 19;271(3):571-4.PMID: 10814503 [PubMed - indexed for MEDLINE]Related articles

    5.

    Hepatocyte growth factor secreted by cultured adipocytes promotes tube formation of vascular endothelial cells in vitro.

    Saiki A, Watanabe F, Murano T, Miyashita Y, Shirai K.

    Int J Obes (Lond). 2006 Nov;30(11):1676-84. Epub 2006 Mar 21.PMID: 16552403 [PubMed - indexed for MEDLINE]Related articles

    6.

    Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

    Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY.

    Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2115-9.PMID: 10892852 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.

    Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S.

    Mol Pharmacol. 2008 Oct;74(4):952-63. Epub 2008 Jul 3.PMID: 18599600 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes.

    Asano A, Irie Y, Saito M.

    Mol Cell Endocrinol. 2001 Mar 28;174(1-2):71-6.PMID: 11306173 [PubMed - indexed for MEDLINE]Related articles

    9.

    Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes.

    Anil Kumar KL, Marita AR.

    Br J Pharmacol. 2000 May;130(2):351-8.PMID: 10807673 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Concentration-dependent stimulatory and inhibitory effect of troglitazone on insulin-induced fatty acid synthase expression and protein kinase B activity in 3T3-L1 adipocytes.

    Barthel A, Krüger KD, Roth RA, Joost HG.

    Naunyn Schmiedebergs Arch Pharmacol. 2002 Apr;365(4):290-5. Epub 2002 Feb 21.PMID: 11919653 [PubMed - indexed for MEDLINE]Related articles

    11.

    Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue.

    Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL.

    Circulation. 2002 Jan 22;105(3):373-9.PMID: 11804995 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

    Baba T, Shimada K, Neugebauer S, Yamada D, Hashimoto S, Watanabe T.

    Diabetes Care. 2001 May;24(5):953-4. No abstract available. PMID: 11347762 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells.

    de Dios ST, Hannan KM, Dilley RJ, Hill MA, Little PJ.

    J Diabetes Complications. 2001 May-Jun;15(3):120-7.PMID: 11358680 [PubMed - indexed for MEDLINE]Related articles

    14.

    Troglitazone and related compounds: therapeutic potential beyond diabetes.

    Fujiwara T, Horikoshi H.

    Life Sci. 2000 Oct 6;67(20):2405-16. Review.PMID: 11065164 [PubMed - indexed for MEDLINE]Related articles

    15.

    Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

    Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR.

    Diabetes. 2002 Jan;51(1):30-6.PMID: 11756319 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes.

    Camp HS, Whitton AL, Tafuri SR.

    FEBS Lett. 1999 Mar 26;447(2-3):186-90.PMID: 10214942 [PubMed - indexed for MEDLINE]Related articles

    17.

    Troglitazone increases system A amino acid transport in 3T3-L1 cells.

    Su TZ, Wang M, Oxender DL, Saltiel AR.

    Endocrinology. 1998 Mar;139(3):832-7.PMID: 9492010 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.

    Kobayashi J, Nagashima I, Hikita M, Bujo H, Takahashi K, Otabe M, Morisaki N, Saito Y.

    Br J Clin Pharmacol. 1999 Apr;47(4):433-9.PMID: 10233209 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.

    Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H.

    Metabolism. 2000 Mar;49(3):411-7.PMID: 10726922 [PubMed - indexed for MEDLINE]Related articles

    20.

    The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.

    Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A.

    Metabolism. 2003 Feb;52(2):173-80.PMID: 12601628 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity